Adjuvant ipilimumab improves survival after high-risk lymph node and melanoma resection
Adjuvant ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but is also associated with a high rate of adverse events.